



UNITED STATES PATENT AND TRADEMARK OFFICE

M
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/085,349	11/16/2001	Victor Gura	30504-2	5267
7590	10/22/2003		EXAMINER	
David E. Heisey, Esq. LUCE, FORWARD, HAMILTON & SCRIPPS LLP Suite 2600 600 West Broadway San Diego, CA 92101			DEAK, LESLIE R	
			ART UNIT	PAPER NUMBER
			3762	
			DATE MAILED: 10/22/2003	

7

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Applicant No.	Applicant(s)	
	10/085,349	GURA, VICTOR	
	Examiner	Art Unit	
	Leslie R. Deak	3762	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 16 November 2001.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-33 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-33 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 03 December 2002 is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some *
 - c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 - a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____	6) <input type="checkbox"/> Other: _____

DETAILED ACTION

Claim Rejections - 35 USC § 112

1. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claims 11-13, 25-26 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Applicant's reference to "additive solutions" is inferentially included in the claim, and does not constitute a positive recitation. Therefore, subsequent claims referring to the additives lack proper antecedent basis.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 1-4, 6, 14-16 18-22, 27-32 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 4,269,708 to Bonomini. Bonomini discloses a wearable dialysis module with capillary fibers that act as dialyzers along with a replaceable filter cartridge 31 that has sorbents that acts to absorb toxins from the dialysis liquid via lines 29 and 23 (see FIG 1, columns 2-5). Bonomini further discloses a blood inlet and outlet (unlabeled, see FIG 1, column 5). Bonomini fails to disclose multiple dialysers or

Art Unit: 3762

multiple sorbent devices, however, mere duplication of the essential working parts of a device amounts to an obvious duplication of the disclosed prior art. See MPEP 2144.04.

5. Claims 5, 17, 20, 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 4,269,708 to Bonomimi in view of US 4,212,738 to Henne. Bonomini discloses the apparatus as claimed with the exception of a deformable casing to conform to the patient. Henne discloses a wearable dialysis system with a flexible casing that's easily conformed to the body of the patient (see column 2). Therefore, it would have been obvious to one of ordinary skill in the art at the time of invention to add a flexible casing to the Bonomini portable dialysis system in order to conform to the body of the patient, as taught by Henne. Henne also discloses a multiple-sheet flat membrane dialyzer as one of the embodiments of his portable dialyzer. The multiple sheets increase the efficiency of the dialyzer (see columns 4, 6). Therefore, it would have been obvious to one of ordinary skill in the art at the time of invention to use a multiple sheet membrane dialyzer in the portable dialysis system disclosed by Bonomini and Henne in order to increase efficiency.

6. Claim 8 is rejected under 35 U.S.C. 103(a) as being unpatentable over US 4,269,708 to Bonomimi in view of US 4,212,738 to Henne, further in view of US 4,897,189 to Greenwood. Bonomini and Henne disclose the apparatus as claimed with the exception of a means for injecting anticoagulant into the blood line. Greenwood discloses that his dialysis apparatus includes means for introducing anticoagulants such as heparin into the bloodstream like those well known in the art to prevent patient blood clots (see column 4). These means for injecting may include ports on the blood inlet or

outlet. Rearranging parts of an invention requires only routine skill in the art. See MPEP 2144.04 Therefore, it would have been obvious to one of ordinary skill in the art at the time of invention to add a means for introducing anticoagulants such as heparin into the dialysis system disclosed by Bonomini in order to prevent patient blood clots.

7. Claim 23 is rejected under 35 U.S.C. 103(a) as being unpatentable over US 4,269,708 to Bonomini in view of US 3,388,803 to Scott. Bonomini discloses the apparatus as claimed with the exception of a port on the diisylate tube. However, Scott discloses ports 27 and 28 in fluid communication with the diisylate. With regard to applicant's recitation drawn to the manner in which the additives are added, such recitation is drawn to the intended use of the device, which does not patentably distinguish from the prior art devices as claimed.

Conclusion

8. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure:

a. US 6,117,122 Din et al
i. Portable dialysis unit

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leslie R. Deak whose telephone number is 703-305-0200. The examiner can normally be reached on M-F 7:30-5:00, every other Friday off.

Art Unit: 3762

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angela Sykes can be reached on 703-308-5181. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0873.

Lrd 
16 October 2003



ANGELA D. SYKES
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700